Triastek
Nanjing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
A biotech innovator using proprietary 3D printing technology to create advanced, programmable oral drug delivery systems.
Gastrointestinal DiseasesCentral Nervous System DiseasesCardiovascular Diseases
Technology Platform
Proprietary Melt Extrusion Deposition (MED) 3D printing technology for pharmaceuticals, enabling the design and manufacture of complex, multi-material oral dosage forms with programmable drug release profiles.
Opportunities
Potential to create new drug delivery paradigms and high-value partnerships with large pharmaceutical companies seeking differentiated products.
Risk Factors
Unproven regulatory pathway for 3D printed drugs and significant technical hurdles in scaling manufacturing to commercial levels.
Competitive Landscape
A pioneer in 3D printed pharmaceuticals with few direct competitors, though it must prove its technology's scalability and cost-effectiveness against traditional formulation science.